Harvard Bioscience (NASDAQ:HBIO) Raised to “Hold” at Wall Street Zen
Harvard Bioscience (NASDAQ:HBIO – Get Free Report) was upgraded by research analysts at Wall Street Zen to a “hold” rating in a research report issued on Friday. A number of other analysts have also weighed in on HBIO. Benchmark lowered their target price on Harvard Bioscience from $4.50 to $3.00 and set a “speculative buy” […]
Harvard Bioscience (NASDAQ:HBIO – Get Free Report) was upgraded by research analysts at Wall Street Zen to a “hold” rating in a research report issued on Friday. A number of other analysts have also weighed in on HBIO. Benchmark lowered their target price on Harvard Bioscience from $4.50 to $3.00 and set a “speculative buy” […]
